## **Appendix 3B**

# New issue announcement, application for quotation of additional securities and agreement

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.

Introduced 01/07/96 Origin: Appendix 5 Amended 01/07/98, 01/09/99, 01/07/00, 30/09/01, 11/03/02, 01/01/03, 24/10/05, 01/08/12, 04/03/13

Schrole Group Ltd	
ABN	
27 164 440 859	
We (the entity) give ASX the following	g information.
<b>Part 1 - All issues</b> You must complete the relevant sections (attack)	h sheets if there is not enough space).
<sup>1</sup> +Class of *securities issued or to be issued	Performance Rights
Number of *securities issued or to be issued (if known) or maximum number which may be issued	45,200,000
Principal terms of the *securities (e.g. if options, exercise price and expiry date; if partly paid *securities, the amount outstanding and due dates for payment; if *convertible securities, the conversion price and dates for conversion)	45,200,000 Performance Rights with a nil exercise price and with vesting conditions set out in the Additional Information Section 4.2 in the Company's prospectus dated 3 July 2018.

Name of entity

<sup>+</sup> See chapter 19 for defined terms.

Do the \*securities rank equally 4 No, the shares issued upon exercise of in all respects from the +issue Performance Rights will rank equally in respect date with an existing +class of from the date of issue with existing fully paid quoted +securities? ordinary shares. If the additional +securities do not rank equally, please state: the date from which they do the extent to which they participate for the next dividend, (in the case of a trust, distribution) interest payment the extent to which they do not rank equally, other than in relation to the next dividend. distribution or interest payment Nil issue price per Performance Right. Issue price or consideration 5 6 Purpose of the issue Issued to employees pursuant to Schrole Group (If issued as consideration for Ltd's Employee Incentive Scheme. the acquisition of assets, clearly identify those assets) 6a Is the entity an +eligible entity that has obtained security holder approval under rule 7.1A? If Yes, complete sections 6b - 6h in relation to the +securities the subject of this Appendix 3B, and comply with section 6i 6b The date the security holder N/A resolution under rule 7.1A was passed 6c Number of \*securities issued N/A without security holder approval under rule 7.1 6d Number of +securities issued N/A with security holder approval under rule 7.1A

6e	Number of *securities issued with security holder approval under rule 7.3, or another specific security holder approval (specify date of meeting)	N/A	
6f	Number of *securities issued under an exception in rule 7.2	N/A	
6g	If *securities issued under rule 7.1A, was issue price at least 75% of 15 day VWAP as calculated under rule 7.1A.3? Include the *issue date and both values. Include the source of the VWAP calculation.	N/A	
6h	If *securities were issued under rule 7.1A for non-cash consideration, state date on which valuation of consideration was released to ASX Market Announcements	N/A	
6i	Calculate the entity's remaining issue capacity under rule 7.1 and rule 7.1A – complete Annexure 1 and release to ASX Market Announcements	N/A	
7	+Issue dates	3 July 2018	
	Note: The issue date may be prescribed by ASX (refer to the definition of issue date in rule 19.12). For example, the issue date for a pro rata entitlement issue must comply with the applicable timetable in Appendix 7A.		
	Cross reference: item 33 of Appendix 3B.		
		Number	+Class
8	Number and *class of all *securities quoted on ASX (including the *securities in section 2 if applicable)	393,746,176	Fully paid ordinary shares
9	Number and +class of all +securities not quoted on ASX (including the +securities in section 2 if applicable)	186,304,055	Fully paid ordinary shares escrowed for 24 months from quotation

<sup>+</sup> See chapter 19 for defined terms.

93,000,000	A Class performance shares subject to Class A milestones as detailed in Prospectus dated 18 August 2017, expiring 5 years from issue, escrowed for 24 months from quotation  B Class performance
93,000,000	shares subject to Class B milestones as detailed in Prospectus dated 18 August 2017, expiring 5 years from issue, escrowed for 24 months from quotation
150,000,000	C Class performance shares subject to Class C milestones as detailed in Prospectus dated 18 August 2017, expiring 5 years from issue, escrowed for 24 months from quotation
9,040,000	Performance Rights with a nil exercise price and with Tranche A Performance Rights vesting conditions as detailed in the Company's prospectus dated 3 July 2018, expiring 5 years from issue
13,560,000	Performance Rights with a nil exercise price and with Tranche B Performance Rights vesting conditions as detailed in the Company's prospectus dated 3 July 2018, expiring 5 years from issue
22,600,000	Performance Rights with a nil exercise price and with Tranche C Performance Rights vesting conditions as detailed in the Company's prospectus dated 3 July 2018, expiring 5 years from issue
25,707,927	Vendor options with exercise price of \$0.04 and expiring 3 years from issue date, escrowed for 24 months from quotation.

Number	+Class
71,292,073	Unlisted options with
	exercise price of \$0.04 and
	expiring 3 years from issue
	date, escrowed for 12
	months from issue;
28,250,000	Unlisted options with
	exercise price of \$0.02,
	expiring 3 years from issue
	date, escrowed for 24
	months from quotation
50,000,000	Unlisted options with
	exercise price of \$0.03,
	expiring 3 years from issue
	date, escrowed for 24
	months from quotation
21,750,000	Unlisted options with
	exercise price of 0.02,
	expiring 3 years from
	quotation, escrowed for 12
	months from issue
7,000,000	Unlisted options with
	exercise price of \$0.03,
	expiring 3 years after issue
	date, escrowed for 24
	months from quotation
7,000,000	Unlisted options with
	exercise price of \$0.04
	(and vesting only if 10-day
	VWAP of the Company's
	share is \$0.04), expiring 3
	years after issue date,
	escrowed 24 months from
	quotation

Dividend policy (in the case of a trust, distribution policy) on the increased capital (interests)

N/A			

#### Part 2 - Pro rata issue - NOT APPLICABLE

#### Part 3 - Quotation of securities

You need only complete this section if you are applying for quotation of securities

- Type of \*securities (tick one)
- (a) +Securities described in Part 1

<sup>+</sup> See chapter 19 for defined terms.

(b)	All other <sup>+</sup> securities
	Example: restricted securities at the end of the escrowed period, partly paid securities that become fully paid, employee incentive share securities when restriction ends, securities issued on expiry or conversion of convertible
	securities

#### Entities that have ticked box 34(a)

#### Additional securities forming a new class of securities

Tick to docum	e you are providing the information or
35	If the *securities are *equity securities, the names of the 20 largest holders of the additional *securities, and the number and percentage of additional *securities held by those holders
36	If the *securities are *equity securities, a distribution schedule of the additional *securities setting out the number of holders in the categories 1 - 1,000 1,001 - 5,000 5,001 - 10,000 10,001 - 100,000 100,001 and over
37	A copy of any trust deed for the additional *securities

#### Entities that have ticked box 34(b) – questions 38-42 not applicable

#### **Quotation agreement**

- <sup>+</sup>Quotation of our additional <sup>+</sup>securities is in ASX's absolute discretion. ASX may quote the <sup>+</sup>securities on any conditions it decides.
- 2 We warrant the following to ASX.
  - The issue of the \*securities to be quoted complies with the law and is not for an illegal purpose.
  - There is no reason why those \*securities should not be granted \*quotation.
  - An offer of the \*securities for sale within 12 months after their issue will not require disclosure under section 707(3) or section 1012C(6) of the Corporations Act.

Note: An entity may need to obtain appropriate warranties from subscribers for the securities in order to be able to give this warranty

• Section 724 or section 1016E of the Corporations Act does not apply to any applications received by us in relation to any \*securities to be quoted and that no-one has any right to return any \*securities to be quoted under sections 737, 738 or 1016F of the Corporations Act at the time that we request that the \*securities be quoted.

- If we are a trust, we warrant that no person has the right to return the \*securities to be quoted under section 1019B of the Corporations Act at the time that we request that the \*securities be quoted.
- We will indemnify ASX to the fullest extent permitted by law in respect of any claim, action or expense arising from or connected with any breach of the warranties in this agreement.
- We give ASX the information and documents required by this form. If any information or document is not available now, we will give it to ASX before †quotation of the †securities begins. We acknowledge that ASX is relying on the information and documents. We warrant that they are (will be) true and complete.

Sign here:	Weller.	Date:	3 July 2018
U	(Director/Company secretary)		
Print name:	Nick Allan		
	== == == ==		

1/00

<sup>+</sup> See chapter 19 for defined terms.

## Appendix 3B – Annexure 1

## Calculation of placement capacity under rule 7.1 and rule 7.1A for eligible entities – Not applicable

Introduced 01/08/12 Amended 04/03/13

#### Part 1

Rule 7.1 – Issues exceeding 15% of capital		
Step 1: Calculate "A", the base figure from which the placement capacity is calculated		
Insert number of fully paid +ordinary securities on issue 12 months before the +issue date or date of agreement to issue		
Add the following:		
<ul> <li>Number of fully paid <sup>+</sup>ordinary securities issued in that 12 month period under an exception in rule 7.2</li> </ul>		
<ul> <li>Number of fully paid <sup>+</sup>ordinary securities issued in that 12 month period with shareholder approval</li> </ul>		
<ul> <li>Number of partly paid <sup>+</sup>ordinary securities that became fully paid in that 12 month period</li> </ul>		
<ul> <li>Note:         <ul> <li>Include only ordinary securities here – other classes of equity securities cannot be added</li> <li>Include here (if applicable) the securities the subject of the Appendix 3B to which this form is annexed</li> <li>It may be useful to set out issues of securities on different dates as separate line items</li> </ul> </li> <li>Subtract the number of fully paid +ordinary</li> </ul>		
securities cancelled during that 12 month period		
"A"		

Step 2: Calculate 15% of "A"			
"B"	0.15 [Note: this value cannot be changed]		
Multiply "A" by 0.15			
Step 3: Calculate "C", the amount of that has already been used	of placement capacity under rule 7.1		
<b>Insert</b> number of *equity securities issued or agreed to be issued in that 12 month period <i>not counting</i> those issued:			
Under an exception in rule 7.2			
Under rule 7.1A			
• With security holder approval under rule 7.1 or rule 7.4			
<ul> <li>Note:</li> <li>This applies to equity securities, unless specifically excluded – not just ordinary securities</li> <li>Include here (if applicable) the securities the subject of the Appendix 3B to which this form is annexed</li> <li>It may be useful to set out issues of securities on different dates as separate line items</li> </ul>			
"C"			
Step 4: Subtract "C" from ["A" x "E placement capacity under rule 7.1	3"] to calculate remaining		
"A" x 0.15			
Note: number must be same as shown in Step 2			
Subtract "C"			
Note: number must be same as shown in Step 3			
<b>Total</b> ["A" x 0.15] – "C"			
	[Note: this is the remaining placement capacity under rule 7.1]		

<sup>+</sup> See chapter 19 for defined terms.

### Part 2

Rule 7.1A – Additional placem	ent capacity for eligible entities	
Step 1: Calculate "A", the base figure from which the placement capacity is calculated		
"A"		
Note: number must be same as shown in Step 1 of Part 1		
Step 2: Calculate 10% of "A"		
"D"	0.10	
	Note: this value cannot be changed	
<i>Multiply</i> "A" by 0.10		
7.1A that has already been used  Insert number of *equity securities issued or agreed to be issued in that 12 month period under rule 7.1A		
<ul> <li>Notes:</li> <li>This applies to equity securities – not just ordinary securities</li> <li>Include here – if applicable – the securities the subject of the Appendix 3B to which this form is annexed</li> </ul>		
<ul> <li>Do not include equity securities issued under rule 7.1 (they must be dealt with in Part 1), or for which specific security holder approval has been obtained</li> <li>It may be useful to set out issues of securities on different dates as separate line items</li> </ul>		

Step 4: Subtract "E" from ["A" x "D"] to calculate remaining placement capacity under rule 7.1A		
"A" x 0.10  Note: number must be same as shown in Step 2		
Subtract "E"  Note: number must be same as shown in Step 3		
<b>Total</b> ["A" x 0.10] – "E"	Note: this is the remaining placement capacity under rule 7.1A	

<sup>+</sup> See chapter 19 for defined terms.